Evaluate the safety and effectiveness of quadrivalent influenza mRNA vaccines (QIV mRNA) compared to standard influenza vaccines. The study aims to assess safety profiles, describe immune responses, and guide future vaccine development.
Active-controlled study to assess the efficacy, safety, and tolerability of investigational drug Baxdrostat in combination with Dapagliflozin compared with Dapagliflozin alone on chronic kidney disease (CKD) progression in participants with CKD and high blood pressure.
Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria.
We are looking for subjects who are affected by uncontrolled hypertension to participate in a research study to investigate a new experimental treatment.
TRIUMPH-3 is a clinical research study for people with excess weight and heart disease. The study will test how safe and well the investigational medicine (the medicine being studied) works for weight management.
This is a clinical research study to test the safety and effectiveness of an investigational medication for uncontrolled and resistant high blood pressure.
The purpose of this clinical trial is to assess the safety and immune response of an investigational vaccine aimed at preventing RSV infection in adults who have had an organ transplant or have preexisting health conditions. All participants in the RSVoice Trial will receive the investigational vaccine.
Doctors are testing an investigational drug to see if it is safe and works well to increase NASH resolution without worsening of fibrosis. Volunteers who have Precirrhotic non-alcoholic steatohepatitis may be able to join.
ACHIEVE-4 is a clinical research study for people with type 2 diabetes and excess weight who are at risk for heart disease or stroke. The study will test how safe and well the investigational medicine (the medicine being studied) works for blood glucose and weight management compared with insulin therapy.
Can I join this study?
Yes, you may be able to join the research study if you:
- Are aged 18 years or over
- Have type 2 diabetes
- Take at least 1 medicine to manage your diabetes
- Have a BMI* of 25 or higher
- Have or are at risk for heart disease, stroke, or other blood vessel diseases, or have kidney disease
*BMI stands for body mass index. If you do not know your BMI, please contact a healthcare professional.
The Future of Flu Starts With You
You have the power to advance research that may change the future of seasonal influenza (flu) with 1 injection. Learn more about participating in the Ignite P303 Trial for an investigational vaccine aimed at preventing seasonal flu infection.
Seasonal flu vaccines during the 2021-2022 flu season were2:
A messenger RNA (mRNA) vaccine may offer broader protection by responding to changes in seasonal flu strains more quickly and creating stronger immune responses3.
The Ignite P303 Trial will look at the safety and immune response of an mRNA-based investigational vaccine aimed at preventing seasonal flu in adults aged 18 and older.
Who Can Join?
This clinical trial is looking for adult participants. To join, you must be:
⚪ 18 years of age or older
⚪ In good health
⚪ Not pregnant or planning on becoming pregnant for at least 3 months following your vaccine visit
Prior to enrolling in this trial, you should:
⚪ Not have received a seasonal flu vaccine in the past 5 months
⚪ Not have had a confirmed flu infection within 5 months
References:
1. Influenza (seasonal): ask the expert: influenza Q&A. World Health Organization. Published November 6, 2018. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
2. Price AM, Flannery B, Talbot HK, et al. Influenza vaccine effectiveness against influenza A(H3N2)-related illness in the United States during the 2021-2022influenza season. Clin Infect Dis. 2022;ciac941. doi:10.1093/cid/ciac941
3. Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG. New technologies for influenza vaccines. Microorganisms. 2020;8(11):1745.
Providing a community-based service and reliable data making possible the advances in the field of Investigational Research for new and better drugs.
Working Hours
Monday-Friday 8:00 AM – 5:00 PM
Saturday (open if necessary)
Sunday (open if necessary)